The purpose of this study is to develop and evaluate a blood test and automated microfluidic test platform for the prenatal screening of fetal aneuploidy.
Study Type
OBSERVATIONAL
Enrollment
2,000
analysis of cell-free DNA in maternal plasma
Royal Prince Alfred Hospital
Sydney, Australia
University Hospital Brugmann
Brussels, Belgium
University of British Columbia
Vancouver, Canada
Hospital CUF Descobertas
Lisbon, Portugal
Comparison of blood test to fetal karyotype
Maternal plasma cell-free DNA will be analyzed to determine copy number of specific chromosomes and compared to the fetal karyotype as obtained through invasive diagnostic testing of the fetus.
Time frame: 21 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hospital Clínico Universitario Virgen de la Arrixaca
Murcia, Spain
University College London Hospital
London, United Kingdom